PRESS RELEASE

Johnson & Johnson Medical Devices Companies announces new neurovascular business

August 1, 2017

Colorado Springs, Co. – Johnson & Johnson Medical Devices Companies* today introduced CERENOVUS,** its new neurovascular business, at the Society of NeuroInterventional Surgery (SNIS) 14th Annual Meeting. CERENOVUS, a name derived from the Latin words for ‘new’ and ‘brain’, will focus on delivering innovative therapies for hemorrhagic and ischemic stroke patients.

Our neurovascular business is evolving and CERENOVUS reflects our bold new vision, positioning and priorities,” said Shlomi Nachman, Company Group Chairman of Johnson & Johnson Medical Devices Cardiovascular & Specialty Solutions. “Inspired by how quickly a stroke can affect a person’s mind and our commitment to reducing the devastating impact, CERENOVUS aims to help physicians give stroke patients a new lease on life.

The Johnson & Johnson Medical Devices Companies are committed to neurovascular care, having expanded CERENOVUS’s product portfolio in the last year with targeted investments. The recent acquisitions of Pulsar Vascular Inc., with a specialty in the endovascular treatment of wide-neck bifurcation aneurysms, and Neuravi Limited, offering extensive expertise and knowledge in acute ischemic stroke with its EmboTrap® Revascularization Platform, greatly extend CERENOVUS’s abilities to address unmet clinical needs in these areas.

Globally, stroke is the second leading cause of death after the age of 60[1]. The American Heart Association estimates someone dies of a stroke every 4 minutes[2]. In the U.S. alone, the economic burden of stroke is estimated at $33 billion annually, which includes the cost of health care services, medications, and lost productivity[3].

About CERENOVUS

CERENOVUS, part of the Johnson & Johnson Medical Devices Companies, is a global leader in neurovascular care. Our commitment to changing the trajectory of stroke is inspired by our long heritage and dedication to helping physicians protect people from a lifetime of hardship. CERENOVUS offers a broad portfolio of devices used in the endovascular treatment of hemorrhagic and ischemic stroke.
Visit www.cerenovus.com for more information.

* The Johnson & Johnson Medical Devices Companies comprise the surgery, orthopaedics, and cardiovascular businesses within Johnson & Johnson’s Medical Devices segment.
** CERENOVUS is part of DePuy Synthes Products, Inc.

1 World Heart Federation
2 Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association
3 Centers for Disease Control

More News